Le marché de l'hypertension artérielle pulmonaire devrait passer de 7 369,89 millions de dollars US en 2021 à 10 889,08 millions de dollars US d'ici 2028 ; on estime qu'il croîtra à un TCAC de 5,8 % de 2022 à 2028.
Le marché de l'hypertension artérielle pulmonaire est segmenté en fonction du médicament, du type, de la voie d'administration, du canal de distribution et de la géographie. Le rapport offre des informations et une analyse approfondie du marché de lhypertension artérielle pulmonaire, en mettant laccent sur divers paramètres tels que la dynamique, les tendances et les opportunités du marché et lanalyse du paysage concurrentiel des principaux acteurs du marché dans diverses régions. Il comprend également l'analyse d'impact de la pandémie de COVID-19 sur le marché de l'hypertension artérielle pulmonaire dans les régions.
Aperçu stratégique
Aperçu du marché
Augmentation des approbations de l'hypertension artérielle pulmonaire Les médicaments stimulent la croissance du marché
- En septembre 2022, Toray Industries, Inc. a reçu l'approbation de l'Administration nationale chinoise des produits médicaux (NMPA) pour les comprimés Careload destinés au traitement des artères pulmonaires l'hypertension (HTAP). Careload est une formulation à libération prolongée administrée par voie orale de beraprost sodique, un dérivé de la prostacycline (PGI2).
- En mai 2022, United Therapeutic Corporation a reçu l'approbation de la Food and Drug Administration (FDA) des États-Unis pour Tyvaso DPI (tréprostinil) poudre pour inhalation pour traiter l'hypertension pulmonaire associée à la pneumopathie interstitielle (PH-ILD ; OMS Groupe 3) et l'hypertension artérielle pulmonaire (HTAP ; OMS Groupe 1) pour améliorer la capacité d'exercice.
- En novembre 2021, la FDA américaine a accordé une approbation provisoire pour la poudre pour inhalation Yutrepia (tréprostinil). Yutrepia est indiqué pour traiter l'HTAP afin d'améliorer la capacité d'exercice chez les patients adultes présentant des symptômes de classe fonctionnelle II-III de la New York Heart Association (NYHA).
- En juillet 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson a reçu l'approbation de la FDA pour l'injection d'UPTRAVI (selexipag) par voie intraveineuse (IV) pour traiter l'HTAP ; Groupe I de l'OMS chez les patients adultes de classe fonctionnelle (FC) II-III de l'OMS, qui sont temporairement incapables de prendre un traitement par voie orale.
- En août 2021, Aerami Therapeutics, Inc. a annoncé que la FDA avait accordé à la société la désignation de médicament pour l'imatinib dans le traitement des patients atteints d'HTAP. AER– 901, un produit candidat combiné médicament-dispositif pour l'imatinib inhalé pour le traitement de l'HTAP, est dans un essai de phase 1 dont l'achèvement est prévu pour la fin de 2021.
L'augmentation des approbations de l'artère pulmonaire les médicaments contre l'hypertension à travers le monde stimulent la croissance du marché de l'hypertension artérielle pulmonaire.
Informations basées sur les médicaments
Sur la base des médicaments, le marché de l'hypertension artérielle pulmonaire est segmenté en antagonistes des récepteurs de l'endothéline (ERA ), prostacycline et analogues de prostacycline, stimulateurs sGC et bandelettes réactives pde-5. Le segment de la prostacycline et des analogues de la prostacycline détenait la plus grande part de marché en 2021 et devrait enregistrer le TCAC le plus élevé en 2022-2028. La prostacycline est une petite molécule eicosanoïde lipidique, également connue sous le nom de prostaglandine, I-2 (PGI-2), produite par les cellules endothéliales et agissant localement, inhibant l'activation plaquettaire et provoquant une vasodilatation. La prostacycline dilate les vaisseaux sanguins, améliore le flux sanguin en empêchant la prolifération des cellules musculaires lisses vasculaires et prévient la coagulation du sang en inhibant l'agrégation plaquettaire. Des analogues de la prostacycline ont été développés comme thérapies pour l'HTAP. Les analogues de la prostacycline PAH sont des formes synthétiques de la prostacycline, une substance naturelle produite dans le corps. Les patients atteints d'HTAP ont tendance à avoir des taux de prostacycline réduits, entraînant une constriction des vaisseaux sanguins et une hypertension. Les analogues de la prostacycline HAP complètent les besoins et imitent l'action de la prostacycline naturelle pour réduire l'hypertension pulmonaire et réduire les symptômes associés.
Marché de l'hypertension artérielle pulmonaire, par médicament &ndash ; 2021–2028
(image) Aperçus basés sur le type
En fonction du type, le marché de l'hypertension artérielle pulmonaire est divisé en produits de marque et génériques. Le segment de marque détenait une plus grande part de marché en 2021 et devrait enregistrer un TCAC plus élevé au cours de la période de prévision. Une société pharmaceutique vend un médicament de marque sous un nom ou une marque spécifique et qui est protégé par un brevet. Les médicaments de marque peuvent être disponibles sur ordonnance ou en vente libre. Riociguat, vendu sous le nom de marque Adempas, est le médicament stimulateur de la guanylate cyclase soluble de Bayer. Il est utilisé pour traiter deux formes d'hypertension pulmonaire - l'hypertension pulmonaire thromboembolique chronique et l'hypertension artérielle pulmonaire.
Voie d'administration basée sur les informations
Selon la voie d'administration, l'hypertension artérielle pulmonaire Le marché est segmenté en administration orale, intraveineuse/sous-cutanée et par inhalation. Le segment oral détenait la plus grande part de marché en 2021 et devrait enregistrer le TCAC le plus élevé au cours de la période de prévision. Les agents administrés par voie orale utilisés pour le traitement de l'HTAP symptomatique modérée à sévère comprennent le sildénafil et les antagonistes des récepteurs de l'endothéline (ET), le bosentan et le sitaxentan (sitaxsentan) et l'ARE sélectif pour les récepteurs ET(A) oraux de l'abrisentan, avec affinité pour le récepteur ET supérieure à celle du bosentan. De plus, les nouveaux médicaments oraux pour le traitement de l'HTAP comprennent le macitentan, le riociguat et le tréprostinil. L'ambrisentan est un antagoniste des récepteurs de l'endothéline indiqué pour le traitement de l'HTAP ; Groupe OMS 1 et retarder l'aggravation clinique. En association avec le tadalafil, l'ambrisentan est indiqué pour réduire les risques de progression de la maladie et d'hospitalisation pour aggravation de l'HTAP, et pour améliorer la capacité d'exercice.
Distribution Channel-Based Insights
Basé sur le canal de distribution , le marché de l'hypertension artérielle pulmonaire est segmenté en pharmacies et cliniques hospitalières, pharmacies en ligne et pharmacies de détail. Le segment des pharmacies hospitalières et des cliniques détenait la plus grande part de marché en 2021 et devrait enregistrer le TCAC le plus élevé au cours de la période de prévision. La pharmacie hospitalière s'efforce de maintenir et d'améliorer en permanence la gestion des médicaments et les soins pharmaceutiques des patients selon les normes les plus élevées en milieu hospitalier. Les pharmaciens de ce domaine sont responsables de la délivrance des médicaments, des tests de qualité, de la formulation et de la reformulation des formes posologiques, de la surveillance, de la notification de la sécurité des médicaments et de la préparation des budgets pour les médicaments.
Les acteurs du marché de l'hypertension artérielle pulmonaire adoptent des stratégies organiques, tels que le lancement et l'expansion de produits, pour étendre leur empreinte et leur portefeuille de produits à travers le monde et répondre à la demande croissante. Les stratégies de croissance inorganiques observées sur le marché sont les partenariats et les collaborations. Ces stratégies de croissance ont permis aux acteurs du marché d'étendre leurs activités et de renforcer leur présence géographique. De plus, les acquisitions, les partenariats et d'autres stratégies de croissance contribuent à renforcer la clientèle de l'entreprise et à augmenter son portefeuille de produits.
- En septembre 2022, Lupin a lancé Sildenafil pour voie orale suspension sur le marché américain avec l'approbation de la FDA américaine. Le médicament est une version générique de Revatio pour suspension buvable de Viatris Specialty LLC. Le sildénafil pour suspension buvable traite l'HAP.
- En février 2021, Aerami Therapeutics, Inc. a signé un accord exclusif de licence et de développement avec Hangzhou Chance Pharmaceuticals Co. Ltd. (Chance) pour développer et commercialiser le médicament d'Aerami candidat-produit de combinaison de dispositifs (« AER-901 ») pour le traitement des HAP en Chine continentale, à Hong Kong, à Macao et à Taïwan. En vertu de l'accord, Chance est responsable du développement global et de la commercialisation de l'AER-901 pour les HAP sur le territoire.
Profils des entreprises
- Johnson & ; Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Novartis AG
- GSK Plc
- Lupin Ltd
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs' arteries. The increased pressure in the vessels may be caused by an obstruction in the lung's small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.
The factors driving the growth of pulmonary arterial hypertension are the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs.
The side effects of drugs used for treating pulmonary arterial hypertension are expected to restrict the pulmonary arterial hypertension market growth during the forecast period.
Pulmonary arterial hypertension majorly consists of the players, such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.
Based on drugs, the pulmonary arterial hypertension market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), sGC stimulators, and pde-5 dipsticks. In 2021, the prostacyclin and prostacyclin analogs segment accounted for a larger market share. Also, the same segment is anticipated to register a higher CAGR during the forecast period as the PAH prostacyclin analogs are used as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.
The global pulmonary arterial hypertension based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, North America held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 6.5% during the forecast period.
The List of Companies - Butterfly Needles Market
- Johnson & Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Novartis AG
- GSK Plc
- Teva Pharmaceutical Industries Ltd
- Lupin Ltd
- Pfizer Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)